![Michael Burnam](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profilo
Michael Burnam has founded Baropace, Inc. in 2018 and currently holds the title of Chief Executive Officer.
Posizioni attive di Michael Burnam
Società | Posizione | Inizio |
---|---|---|
Baropace, Inc.
![]() Baropace, Inc. Electronic Equipment/InstrumentsElectronic Technology Baropace, Inc. is a privately held medical device company located in Ashland, OR. Baropace is focused on the development of pressurepace™, a real-time physiologic control software and hardware to regulate cardiac pacemakers to treat resistant hypertension and heart failure with preserved ejection fraction (hfpef). The company has proprietary biotechnologies including a pacemaker control algorithm (pressurepace™) and new sensor technologies working through patient mobile and wearable platforms. Baropace expects to launch a first-in-human clinical trial (relievehtn-i) in the fourth quarter of 2022. Pressurepace™ is limited by federal law to investigational use only and is not approved for sale in any geography. The company was founded in 2019 by Eli Gang and Michael Burnam, who has been the CEO since 2018. | Amministratore Delegato | 01/01/2018 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 1 |
---|---|
Baropace, Inc.
![]() Baropace, Inc. Electronic Equipment/InstrumentsElectronic Technology Baropace, Inc. is a privately held medical device company located in Ashland, OR. Baropace is focused on the development of pressurepace™, a real-time physiologic control software and hardware to regulate cardiac pacemakers to treat resistant hypertension and heart failure with preserved ejection fraction (hfpef). The company has proprietary biotechnologies including a pacemaker control algorithm (pressurepace™) and new sensor technologies working through patient mobile and wearable platforms. Baropace expects to launch a first-in-human clinical trial (relievehtn-i) in the fourth quarter of 2022. Pressurepace™ is limited by federal law to investigational use only and is not approved for sale in any geography. The company was founded in 2019 by Eli Gang and Michael Burnam, who has been the CEO since 2018. | Electronic Technology |
- Borsa valori
- Insiders
- Michael Burnam